Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Transplant Proc ; 50(1): 130-136, 2018.
Article in English | MEDLINE | ID: mdl-29407295

ABSTRACT

BACKGROUND: Data on BK virus-associated nephropathy (BKVAN) and treatment strategy in a resource-limited country are scarce. This study aimed to evaluate epidemiology of BKVAN and its situation in Thailand. METHODS: A retrospective analysis was conducted among adult kidney transplant recipients at Ramathibodi Hospital from October 2011 to September 2016. Patients' demographic data, information on kidney transplantation, immunosuppressive therapy, cytomegalovirus and BK virus infections, and allograft outcomes were retrieved and analyzed. RESULTS: This study included 623 kidney transplant recipients. Only 327 patients (52.49%) received BK virus infection screening, and 176 of 327 patients had allograft dysfunction as a trigger for screening. BKVAN was identified in 39 of 327 patients (11.93%). Deceased donor transplantation and cytomegalovirus infection were associated with a higher risk of BKVAN (odds ratio = 2.2, P = .024, 95% confidence intervals [1.1, 4.43], and odds ratio = 2.6, P = .006, 95% confidence intervals [1.29, 5.26], respectively). BKVAN patients were at significantly higher risk for allograft rejection (P < .001) and allograft failure (P = .036). At the end of the study, 4 graft losses were documented (12.12%). CONCLUSIONS: BKVAN was associated with high rate of allograft rejection and failure. However, surveillance of its complications has been underperformed at our facility. Implementing a formal practice guideline may improve allograft outcome in resource-limited countries.


Subject(s)
BK Virus , Kidney Diseases/epidemiology , Kidney Transplantation/adverse effects , Polyomavirus Infections/epidemiology , Postoperative Complications/epidemiology , Tumor Virus Infections/epidemiology , Adult , Developing Countries , Female , Humans , Immunosuppression Therapy/adverse effects , Kidney Diseases/virology , Male , Middle Aged , Odds Ratio , Polyomavirus Infections/virology , Postoperative Complications/virology , Retrospective Studies , Risk Factors , Thailand/epidemiology , Transplantation, Homologous/adverse effects , Tumor Virus Infections/virology
3.
Med Mycol ; 56(2): 186-196, 2018 Feb 01.
Article in English | MEDLINE | ID: mdl-28525619

ABSTRACT

Formal, large-scale, multicenter studies of invasive mould infection (IMI) in Asia are rare. This 1-year, retrospective study was designed to assess the incidence and clinical determinants of IMI in centers in five countries (Thailand, Taiwan, Singapore, China, India). Patients treated in a single year (2012) were identified through discharge diagnoses, microbiology, and histopathology logs, and entered based on published definitions of IMI. A total of 155 cases were included (median age 54 years; 47.7% male). Of these, 47.7% had proven disease; the remainder had probable IMI. The most frequent host factors were prolonged steroid use (39.4%) and recent neutropenia (38.7%). Common underlying conditions included diabetes mellitus (DM; 30.9%), acute myeloid leukemia (19.4%), and rheumatologic conditions (11.6%). DM was more common in patients with no recent history of neutropenia or prolonged steroid use (P = .006). The lung was the most frequently involved site (78.7%), demonstrating a range of features on computed tomography (CT). Aspergillus was the most common mould cultured (71.6%), primarily A. fumigatus and A. flavus, although proportions varied in different centers. The most often used antifungal for empiric therapy was conventional amphotericin. Ninety-day mortality was 32.9%. This is the first multicenter Asian study of IMI not limited to specific patient groups or diagnostic methods. It suggests that DM and rheumatologic conditions be considered as risk factors for IMI and demonstrates that IMI should not be ruled out in patients whose chest features on CT do not fit the conventional criteria.


Subject(s)
Fungi/physiology , Invasive Fungal Infections/epidemiology , Invasive Fungal Infections/microbiology , Adolescent , Adult , Aged , Aged, 80 and over , Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Asia/epidemiology , Aspergillus/physiology , Child , Child, Preschool , Female , Humans , Incidence , Invasive Fungal Infections/diagnosis , Invasive Fungal Infections/drug therapy , Lung/diagnostic imaging , Male , Middle Aged , Retrospective Studies , Risk Factors , Treatment Outcome , Young Adult
4.
Transplant Proc ; 49(5): 1048-1052, 2017 06.
Article in English | MEDLINE | ID: mdl-28583524

ABSTRACT

BACKGROUND: Data on drug-resistant cytomegalovirus (CMV) infection in solid organ transplantation (SOT) are not often reported from resource-limited settings. We aimed to investigate the epidemiology and outcomes of this infection in SOT recipients at our institution. METHODS: This was a retrospective study conducted from January 2012 to May 2015. We included all SOT recipients who were suspected for drug-resistant CMV infection. Genotypic assay for UL97 gene mutation was analyzed by real-time polymerase chain reaction. Patients were reviewed for demographic data, clinical presentation, virologic data, treatment, and outcomes. RESULTS: The population consisted of 18 (12 kidney, 6 liver) SOT recipients with a median age of 20 years (interquartile range [IQR], 1-49); 44% were male. Anti-CMV resistance testing was analyzed at a median time of 23 days (IQR, 14-33) after initiation of anti-CMV therapy with a median CMV load of log 3.79 copies/mL (IQR, 3.37-4.58). During a median period of 2 years (IQR, 1-3), 6 SOT recipients were identified with UL97 gene mutation in codon 460, conferring ganciclovir (GCV) resistance. Patients with UL97 gene mutation had a longer mean duration of CMV DNAemia compared with those without mutation (263 vs 107 days; P = .04). All patients received high-dose GCV. Two patients received foscarnet and cidofovir. Two patients died (non-CMV-related), and 4 patients developed opportunistic infections other than CMV. CONCLUSIONS: GCV-resistant CMV infection in SOT recipients is an emerging clinical problem in resource-limited country. Those with UL97 mutation CMV infection have prolonged duration of CMV DNAemia. Clinicians should be aware of this condition when caring for SOT recipients.


Subject(s)
Cytomegalovirus Infections/epidemiology , Cytomegalovirus/genetics , Drug Resistance, Viral/genetics , Organ Transplantation/adverse effects , Postoperative Complications , Adult , Antiviral Agents/therapeutic use , Cidofovir , Cytomegalovirus Infections/drug therapy , Cytomegalovirus Infections/virology , Cytosine/analogs & derivatives , Cytosine/therapeutic use , Female , Foscarnet/therapeutic use , Ganciclovir/therapeutic use , Humans , Kidney Transplantation/adverse effects , Liver Transplantation/adverse effects , Male , Middle Aged , Mutation , Organophosphonates/therapeutic use , Real-Time Polymerase Chain Reaction , Retrospective Studies , Thailand/epidemiology , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...